CAS NO: | 1239908-20-3 |
规格: | ≥98% |
包装 | 价格(元) |
50mg | 电议 |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
1g | 电议 |
Ixazomib citrate (MLN9708; MLN-9708; MLN 9708), the citrate salt and orally bioavailable prodrug of Ixazomib (MMLN2238; MMLN-2238), is a selective inhibitor of 20S proteasome (IC50 = 3.4 nM) with potential anticancer activity. It is being studies in a Phase II trial to treat multiple myeloma, amyloidosis and lymphoma in sorts of countries. Ixazomib citrate is a boron-containing compound that has to be hydrolyzed to MLN2238 (ixazomib) which is pharmacologically active. Compared with bortezomib, MLN9708 has improved pharmacokinetics, pharmacodynamics, and antitumor activity in preclinical studies.
纯度:≥98%
CAS:1239908-20-3